Springbank 10
Selected indexed studies
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. (Gut, 2022) [PMID:34001645]
- Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. (Lancet Glob Health, 2022) [PMID:35063115]
- Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. (Nat Med, 2021) [PMID:34642494]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. (2022) pubmed
- Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. (2022) pubmed
- Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. (2021) pubmed
- Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. (2023) pubmed
- Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. (2022) pubmed
- Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study. (2024) pubmed
- Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure. (2025) pubmed
- Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment. (2025) pubmed
- Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. (2025) pubmed
- Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors. (2025) pubmed